GlassScriptPhysician profile
Cheryl L Williams
NPI 1730187204
$9,266.29
in general payments reported to CMS, 2019-2025
58 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $1,034 · 2021: $1,417 · 2022: $1,292 · 2023: $1,430 · 2024: $1,290 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,264 · Education: $4.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.98 |
| Education | $4.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,043.05 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $860.36 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $582.28 | 2019-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $470.58 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Glaxosmithkline, LLC. | $385.46 | 2019-2021 | |
| Astellas Pharma US INC | $383.68 | 2019-2025 | Veozah |
| Abbvie INC. | $379.39 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Janssen Pharmaceuticals, INC | $367.33 | 2019-2023 | Xarelto |
| Alkermes, INC. | $355.05 | 2023-2025 | Aristada, Lybalvi |
| Abbott Laboratories | $354.45 | 2021-2025 | Freestyle Libre |
| Lilly USA, LLC | $340.05 | 2019-2023 | Mounjaro, Trulicity |
| Teva Pharmaceuticals USA, INC. | $290.23 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Dexcom, INC. | $255.28 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $242.59 | 2019-2023 | Verquvo, Dificid, Pifeltro |
| Novo Nordisk INC | $206.60 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.